Literature DB >> 8099064

Protective anti-idiotype antibodies in the primate model of pyelonephritis.

M B Kaack1, L N Martin, S B Svenson, G Baskin, R H Steele, J A Roberts.   

Abstract

The adherence of P-fimbriated Escherichia coli to a receptor containing alpha-D-Gal-(1-4)-beta-D-Gal (Gal-Gal) on urothelial cells is an important pathogenic mechanism in the development of pyelonephritis. Antibodies (Ab1) that had been produced by immunization with Gal-Gal conjugated with bovine serum albumin were specifically purified and used to stimulate the production of anti-idiotypic antibodies (Ab2) in cynomolgus monkeys (Macaca fascicularis). While sera from all of the Ab2-producing monkeys contained antibodies reactive with Ab1 and P-fimbriae, not all of the sera inhibited P-fimbrial binding to the Gal-Gal receptor. On the basis of the inhibition of binding, Ab2-producing monkeys were divided into two groups, termed reactive and nonreactive. The reactive and nonreactive Ab2-producing monkeys, together with a group of control monkeys, were challenged with a renal inoculation with P-fimbriated Escherichia coli. Hematologic, immunologic, microbiologic, and pathologic data were compared among the three groups. The reactive monkeys, whose Ab2 in serum inhibited binding between P-fimbriae and the Gal-Gal receptor, were protected against renal damage compared with the control group. The nonreactive group shared some parameters with the reactive group but overall developed renal damage comparable to that of the controls.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8099064      PMCID: PMC280847          DOI: 10.1128/iai.61.6.2289-2295.1993

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  16 in total

1.  P-fimbriae vaccines. II. Cross reactive protection against pyelonephritis.

Authors:  J A Roberts; M B Kaack; G Baskin; T K Korhonen; S B Svenson; J Winberg
Journal:  Pediatr Nephrol       Date:  1989-10       Impact factor: 3.714

2.  New Method for isolation of immunologically pure pili from Escherichia coli.

Authors:  T K Korhonen; E L Nurmiaho; H Ranta; C S Edén
Journal:  Infect Immun       Date:  1980-02       Impact factor: 3.441

3.  Implications of the presence of an internal image of the antigen in anti-idiotypic antibodies: possible application to vaccine production.

Authors:  A Nisonoff; E Lamoyi
Journal:  Clin Immunol Immunopathol       Date:  1981-12

4.  Immunology of pyelonephritis in the primate model. VI. Effect of complement depletion.

Authors:  J A Roberts; J K Roth; G Domingue; R W Lewis; B Kaack; G Baskin
Journal:  J Urol       Date:  1983-01       Impact factor: 7.450

5.  Rapid identification of P-fimbriated Escherichia coli by a receptor-specific particle agglutination test.

Authors:  S B Svenson; G Källenius; R Möllby; H Hultberg; J Winberg
Journal:  Infection       Date:  1982       Impact factor: 3.553

Review 6.  P-fimbriae of pyelonephritogenic Escherichia coli: identification and chemical characterization of receptors.

Authors:  S B Svenson; H Hultberg; G Källenius; T K Korhonen; R Möllby; J Winberg
Journal:  Infection       Date:  1983 Jan-Feb       Impact factor: 3.553

7.  Experimental pyelonephritis. V. Functional characteristics of pyelonephritis.

Authors:  K L Janson; J A Roberts
Journal:  Invest Urol       Date:  1978-03

8.  Immunology of pyelonephritis in the primate model. V. Effect of superoxide dismutase.

Authors:  J A Roberts; J K Roth; G Domingue; R W Lewis; B Kaack; G Baskin
Journal:  J Urol       Date:  1982-12       Impact factor: 7.450

9.  Immunization of mice against African trypanosomiasis using anti-idiotypic antibodies.

Authors:  D L Sacks; K M Esser; A Sher
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

10.  Quantitative investigations of idiotypic antibodies. I. Analysis of precipitating antibody populations.

Authors:  H Daugharty; J E Hopper; A B MacDonald; A Nisonoff
Journal:  J Exp Med       Date:  1969-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.